The *Urtica Dioica* Agglutinin Prevents Rabies Virus Infection in a Muscle Explant Model

Xinyu Wang[1,5], Lisanne Terrie[2], Guanghui Wu[3], Els J.M. Van Damme[4], Anthony R Fooks[3], Ashley C Banyard[3], Lieven Thorrez[2], Dirk Jochmans[1,5*], Johan Neyts[1,5*]

Affiliations:

[1] KU Leuven, Rega Institute, Department of Microbiology, Immunology and Transplantation, Leuven, Belgium.

[2] KU Leuven, Campus Kulak, Department of Development and Regeneration, Tissue Engineering Lab, Kortrijk, Belgium

[3] Animal and Plant Health Agency (APHA), Woodham Lane, Weybridge, Surrey KT15 3NB, UK.

[4] Ghent University, Faculty of Bioscience Engineering, Gent, Department of Biotechnology, Belgium

[5] Global Virus Network (GVN)

*Corresponding authors: dirk.jochmans@kuleuven.be and johan.neyts@kuleuven.be

Key words: antiviral, rabies virus, lectin, muscle explant

Abstract

Infection with the rabies virus (RABV) results, once symptoms develop, in a 100% lethal neurological disease. Post-exposure prophylaxis (PEP), consists of a combination of vaccination and anti-rabies immunoglobulins (RIGs); it is 100% effective if administered early after infection. Because of the limited availability, alternatives for RIGs are needed. To that end we evaluated a panel of 33 different lectins for their effect on RABV infection in cell culture. Several lectins, with either mannose or GlcNAc specificity elicited anti-RABV activity of which the GlcNAc specific *Urtica dioica* Agglutinin (UDA) was selected for further studies. UDA was found to prevent entry of the virus into the host cell. To further assess the potential of UDA, a physiologically relevant RABV infection muscle explant model was developed. Strips of dissected swine skeletal muscle that were kept in culture medium could be productively infected with the RABV. When the infection of the muscle strips was carried out in the presence of UDA, RABV replication was completely prevented. We thus developed a physiologically relevant RABV muscle infection model. UDA (i) may serve as a reference for further studies and (ii) holds promise as a cheap and simple to produce alternative for RIGs in PEP.

39 # Introduction

40 Rabies virus (RABV), a member of the Lyssavirus genus, is a neurotropic virus that causes an
41 acute and fatal encephalitis in humans and animals. The incubation period in most patients is
42 20-90 days [1], and, upon onset of symptoms, the disease is nearly 100% fatal. Post exposure
43 prophylaxis (PEP), in the form of vaccination and injection of rabies immunoglobulins (RIG)
44 in and around the wound shortly after exposure, can prevent infection [2]. However, RIGs are
45 scarce in endemic regions [3,4] due to their short shelf-life, the need for a cold chain and the
46 high cost of manufacturing. It is estimated that less than 2% of severely exposed patients
47 (category III) receive RIGs worldwide [5,6].

48 Humans are most commonly exposed to rabies when bitten by rabid animals with infectious
49 virus in their saliva. If the dermal barrier is breached, the virus infects muscle cells and gains
50 access to neuronal cells through the neuromuscular junctions (NMJ). Once within neuronal
51 cells the virus migrates from the peripheral nerves to the central nervous system (CNS) resulting
52 in replication in the brain and the development of rabies. The disease is characterized by an
53 altered mental status, hydrophobia, aerophobia, or inspiratory spasms [7]. To enable cell entry,
54 the nicotinic acetylcholine receptor (nAChR) serves as one of the key receptor molecules for
55 rabies virus binding and entry [8–10]. However, the nAChR tends to be concentrated at the
56 postsynaptic muscle membrane in the NMJ, which may drive accumulation of rabies virions
57 near the NMJ enhancing the likelihood of the virus entering the peripheral neuron or motor
58 neuron [11,12]. To this end, it is important to inhibit RABV accumulation or replication in
59 muscle cells and prevent infection of the nervous system. This mechanism of action is proposed
60 for RIGs, which are injected in the tissue near the exposure wound.

61 Lectins are a group of carbohydrate-binding proteins from plants, fungi, animals or bacteria
62 that can also be produced by recombinant DNA techniques [13]. Since the initial discovery of
63 lectins more than 100 years ago, they became a focus of attention in many biological processes,
64 including glycoprotein recognition, cell-cell communication, interaction with infectious agents,
65 recruitment of leukocytes to inflammatory sites and tumor metastasis [13,14]. Several lectins,

66 mostly with mannose and N-acetylglucosamine specificity elicit antiviral activity against HIV
67 through binding to gp120 [15,16] and inhibition of viral entry [17]. HHA, a mannose specific
68 lectin from *Hippeastrum Hybrid* has been reported to inhibit SARS-CoV at the stage of viral
69 attachment and fusion [18]. UDA, a N-acetylglucosamine specific lectin from *Urtica dioica*
70 inhibits SARS-CoV-2 infection of cells by binding to the spike protein [19]. Some lectins were
71 shown to reduce infection of cells with the RABV [20,21].

72 We here identified several other lectins that inhibit RABV infection *in vitro*. To assess in a
73 physiological relevant infection model, the potential of lectins as alternatives for RIGs, we
74 established a RABV infection model in swine muscle strips. We demonstrate in this model that
75 UDA, an N-acetylglucosamine specific lectin from the Stinging nettle (*Urtica dioica*)
76 efficiently inhibits RABV infection in this muscle model.

77 # Materials and methods

78 ## Cells, virus and lectins

79 Rabies virus SAD-B19-mCherry was obtained from the laboratory of Professor Anthony Fooks
80 (Animal & Plant Health Agency, UK). BHK-21J cells (ATCC CCL-10™) were propagated in
81 Dulbecco's Modified Eagle Medium (DMEM) (ThermoFisher Scientific) with 10% fetal bovine
82 serum (FBS) (Hyclone) and penicillin-streptomycin (P/S) (100 U/mL, ThermoFisher Scientific).
83 When cells were infected with RABV, 2% DMEM was used. Lectins were obtained from
84 Professor Els Van Damme (Ghent University, Belgium), then were dissolved in PBS at 1 mg/mL
85 and stored at -20 °C.

86 ## Antiviral assay

87 Compounds were added to cells in a 2-fold serial dilution from 100 μg/mL to 0.8 μg/mL,
88 followed by virus at a multiplicity of infection (MOI) of 0.01 $TCID_{50}$/cell. Antiviral activity
89 was measured by quantification of the amount of mCherry fluorescence on day 5 post-infection
90 (SPARK, Tecan, Belgium). Cell viability was determined by an MTS assay as described
91 previously[22]. The half maximal effective concentration (EC_{50}) of antiviral effect and half
92 maximal cytotoxic concentration (CC_{50}) was derived from the corresponding dose–response
93 curves.

94 ## Time of drug addition assay

95 UDA, at a final concentration of 25 μg/mL, was added to RABV infected (MOI =1) cell cultures.
96 To determine if UDA has an impact on viral adsorption and attachment, cells were incubated
97 with RABV at 4°C for 1h (-1 – 0 h) with or without UDA. After the incubation, to investigate
98 if UDA inhibits viral entry, the unattached virus was washed away 3 times with PBS.
99 Subsequently, cells were incubated at 37°C and UDA was added at different time points (0, 0.5,
100 1, 2, 4 h.p.i., Figure 2). Infected cells without compound treatment were defined as untreated
101 controls, and untreated samples collected at 1 h.p.i. were considered as virus background. At
102 16 h.p.i., viral RNA was extracted from the cells (E.Z.N.A. Total RNA Kit I R6834-01, Omega

103 BIO-TEK) and quantified by RT-qPCR analysis.

104 Pre-incubation of RABV to lectins prior to infection

105 RABV (MOI=0.4) was incubated with UDA (25µg/mL) at 37 °C for 2 h. Then, the mixture of
106 virus and compound was diluted and added to BHK cells and incubated at 37 °C (virus final
107 MOI was 0.1, UDA final concentration was 1 µg/mL). After 3 days, the viral mCherry
108 fluorescence was quantified (SPARK®, Tecan, Belgium). The result was defined as "Pre-
109 Incubation Virus".

110 Pre-incubation of BHK to lectins prior to infection

111 The monolayer of BHK cells was pre-incubated with 25 µg/mL UDA at 37 °C for 2 hours. Then,
112 the compound was diluted by adding the virus suspension and incubated at 37 °C (virus final
113 MOI was 0.1, UDA final concentration was 1 µg/mL). After 3 days, the viral mCherry
114 fluorescence was quantified as above. This result was defined as "Pre-Incubation Cells"

115 Swine skeletal muscle explant culture and antiviral assay

116 The biceps femoris muscle was dissected from freshly euthanized pigs (3 months, female),
117 obtained as residual tissue from ORSI Academy (Melle, Belgium). The muscle biopsy was
118 dissected, parallel to the muscle fibers, in 2 cm long 2 mm thick strips using sterile scalpels.
119 Tissue strips were maintained under tension using minutia pins (Entosphinx, stainless steel pins,
120 diameter 0.25 mm) on sterile sylgard coated wells of a 6-well plate. During maintenance tissue
121 strips were cultured (37°C, 5% CO_2) submerged in DMEM with 10% FBS and P/S (100 U/mL),
122 and in DMEM with 2% FBS and P/S during the antiviral experiments. For antiviral testing,
123 muscle explants were incubated with 25 µg/mL UDA at 37 °C for 2h. Then they were inoculated
124 with 2×10^4 $TCID_{50}$ RABV while the UDA concentration was kept constant at 25 µg/mL. After
125 4 h incubation, muscle explants were washed 5 times with PBS, and maintained with 25 µg/mL
126 UDA for 6 days. For the untreated control, muscle strips were inoculated with same amount of
127 virus but without UDA treatment. A sample of 300 µL of the culture SN was collected every
128 day for untreated control for RT-qPCR analysis, and on day 6 for UDA treated sample for

129 determination of infectious virus respectively.

130 Muscle culture supernatant titration

131 The titer of infectious virus, present in swine muscle explant supernatant at day 6, was
132 determined by 10-fold serial dilution on confluent BHK cells. On day 7, virus expressed
133 fluorescence was quantified using microscopy and the $TCID_{50}$ was calculated by the Spearman–
134 Kärber method.

135 Muscle explant viability assay

136 Muscle stripes were incubated with UDA at 25 µg/mL for 7 days. On each day, a resazurin-
137 based toxicity assay was conducted: The medium of muscle stripes was removed and replaced
138 by 1ml resazurin (PrestoBlue™ HS cell viability reagent P50200, ThermoFisher) working
139 solution (10% PrestoBlue regent in PBS) followed by incubation at 37°C for 2h. Then, 200 µL
140 resazurin working solution was transferred to a transparent 96-well plate. The fluorescence was
141 measured at excitation 560nm and emission 590nm. In living cells, the cell-permeable, non-
142 fluorescent resazurin is reduced to the red highly fluorescent resorufin. As resazurin is
143 continuously converted into resorufin, the fluorescence is a quantitative indicator of the cell
144 viability and cytotoxicity.

145 Fluorescent immunostaining and microscopy of muscle

146 On day 6 p.i. swine skeletal muscle explants were washed 5 times with PBS, fixed in 4%
147 formaldehyde for 1 h and stored at 4 °C in PBS until staining. Before imaging, they were
148 permeabilized with ice-cold 80% acetone at room temperature for 1 h and washed 5 times in
149 PBS. Next, muscle explants were incubated 1 h at 37 °C with FITC Anti-Rabies Monoclonal
150 Globulin (800-092, Fujirebio) diluted 1:10 in PBS. After 5 times PBS washing, muscle explants
151 were incubated in 5µg/mL Hoechst (H1399, Invitrogen) for 15 min at room temperature.
152 Imaging was performed using the Leica DMi8 S Platform with Leica Application Suite X
153 software (Leica, Heidelberg, Germany). All pictures were obtained with a 10× objective and z
154 position between 1820 µm to 1950 µm.

155 **Real-time RT-qPCR**

156 Rabies virus N gene was amplified by real-time quantitative PCR using iTaq™ Universal
157 SYBR® Green One-Step Kit (BIO-RAD). The primers are as follow: 5'-
158 TGGGCACAGTTGTCACTGCTTA-3' (forward) and 5'-CTCCTGCCCTGGCTCAA-3'
159 (reverse). The standard curve was generated from the RNA extraction of the 1/10 diluted virus
160 stock (2.2 × 10^6 $TCID_{50}$/mL). A 20 µL qPCR reaction contains 4 µL extracted sample RNA or
161 standard, 10 µL iTaq Universal SYBR® Green reaction mix, 0.25 µL reverse transcriptase and
162 600 nM of each forward and reverse primer. qPCR was performed in a Roche LightCycler 96
163 with the procedure: 10 min at 50 °C for reverse transcription, 1 min at 95 °C for polymerase
164 activation and DNA denaturation, 40 cycles of 95 °C 15s and 62 °C 30s for PCR amplification.
165 Viral copies were calculated based on a standard curve using control material.

166 **Statistics**

167 Statistical analysis in this study was done by GraphPad Prism 9. A P-value less than 0.05 was
168 considered as statistically significant. P values associated with each graph are indicated as: *,
169 P value < 0.05; **, P value < 0.01; ***, P value < 0.001; ****, P value < 0.0001.

170 # Results

171 **Several lectins inhibit RABV in cell culture**

172 The effect of 33 lectins on RABV infection of BHK cells was assessed using a reporter virus
173 (SAD-B19-mCherry). Several lectins were identified that elicit antiviral activity (Table 1). The
174 GlcNAc-specific agglutinin *Urtica dioica* Agglutinin (UDA) and the mannose-specific BanLec
175 from *Musa acuminata* (banana) and PSA from *Pisum sativum* (pea) were most potent and
176 selective. These activities were confirmed in a follow-up experiment with the same method as
177 the screening (EC_{50}s UDA: 4.6 µg/mL; BanLec: 6.0 µg/mL; PSA: 18 µg/mL) (CC_{50}s UDA: 65
178 µg/mL; BanLec: 36 µg/mL; PSA: >100 µg/mL) (Figure 1). UDA (which we had available in
179 larger quantities), was selected for further study. To explore at which step of the virus replication
180 cycle UDA exerts its activity the lectin was added to the infected cultures at various times pre-
181 and post-infection. When only present during the binding process at 4°C (from time -1 hr – 0
182 hr) (p.i.), no antiviral effect was measured. When UDA was however also present when the
183 temperature was shifted to 37°C (which allows entry of the virus), the lectin prevented RABV
184 infection. When addition of UDA to the cultures was delayed for one or two hours after the
185 temperature shift, there was a gradual loss in antiviral activity (Figure 2). Together this indicates
186 that UDA blocks RABV replication at the entry, but not the binding step. To investigate whether
187 UDA interacts with the virus or the cells, either virus or cells were pre-incubated with 25 µg/ml
188 UDA at 37°C for 2 hours after which the mix was diluted to a non-inhibitory concentration and
189 was mixed with cells or virus, respectively. The RABV infection was quantified by measuring
190 the viral fluorescence signal at 3 days p.i. Pre-incubation of the cells with UDA was more
191 efficient in blocking the viral signal ($p < 0.0001$) than when virus was preincubated with UDA,
192 indicating that the predominant mechanism of action may be the results of an interaction of the
193 lectin with the host cell (Figure 3).

194 **RABV replicates in swine skeletal muscle explants**

195 *Biceps femoris* muscle samples (2 cm long, 2 mm thick) were dissected from freshly euthanized
196 3-month-old female pig and maintained *ex vivo* under tension using pins (Figure 4A). In a first

197 step we explored whether RABV can replicate in this muscle tissue. The explant cultures were
198 inoculated with 2×10^4 $TCID_{50}$ of virus for 4h. Next, the viral inoculum was removed and the
199 muscle strips were washed 5 times by PBS. The culture supernatant was collected every day
200 for 6 consecutive days to determine the viral RNA load. On day 5-6 post-infection, viral RNA
201 in the culture supernatant was >10 fold higher as compared to day 0 (Figure 4B). To confirm
202 that infectious virus is produced, the culture medium obtained from the muscle cultures on day
203 6 was used to inoculate BHK cells. The mCherry red fluorescence expressed by the virus was
204 observed in BHK cells infected with this day 6 inoculum (Figure 4C) demonstrating that swine
205 skeletal muscles can be productively infected with RABV.

206 **UDA inhibits RABV infection in swine skeletal muscle**

207 To investigate whether UDA can prevent RABV infection of muscle tissue, the muscle strips
208 were pre-incubated with UDA (25 µg/mL) for 2 h followed by virus inoculation in presence or
209 absence of UDA. After 4 h the virus inoculum was removed and new medium, with or without
210 UDA (25 µg/mL), was added. On day 6 post-infection, the culture supernatant was collected
211 for titration on BHK cells and the muscle tissues were fixed for immunofluorescence staining.
212 UDA treatment resulted in a significant decrease in virus production in the medium (Figure 5B)
213 and in antigen expression in the cells (Figure 5C). At a concentration of 25 µg/mL UDA had no
214 adverse effect on the viability of the muscle strips during the 7 days exposure period (Figure
215 5A).

216 ## Discussion

217 Rabies immunoglobulins (RIG) are used, together with vaccination, in RABV post exposure
218 prophylaxis (PEP) after high-risk exposure. RIGs provide passive protection by neutralizing
219 the virus in the wound and surrounding tissues. Due to the high cost and supply shortages of
220 RIGs, the WHO recommends since the 1990's the development of alternatives [23]. Some
221 monoclonals have been licensed for respectively the Indian (Rabishield and Twinrab) [24] and
222 Chinese (Ormutivimab) market, but suffer obviously from the same shortcomings [5].

223 In an attempt to develop an alternative for RIGs, we explored whether a series of lectins (with
224 various specificities), that are easy and cheap to produce and that do not require a cold-chain,
225 may prevent entry of RABV in cells. We identified that the GlcNAc-specific agglutinin UDA
226 from *Urtica dioica* (stinging nettle), the mannose specific lectins BanLec and PSA respectively
227 from *Musa acuminata* (banana) and *Pisum sativum* (pea) as the most potent and selective
228 inhibitors of infection within this series. UDA, (which was readily available to us) was selected
229 for further studies. Others have reported that the mannose/glucose specific lectin Concanavalin
230 A (con A) prevents RABV entry in cells, but we here observed that the antiviral and cytotoxic
231 effects of con A are nearly overlapping [21]. Time-of-drug-addition studies and an experiment
232 in which either the virus or the cells were preincubated with UDA indicate that this lectin
233 prevents entry (not binding) of the virus in the cells and does so predominantly by interacting
234 with the host cell. Lectins are characterized by their reversible binding to a specific mono- or
235 oligosaccharide [25]. Several lectins have been reported to exert anti-bacterial and antiviral
236 activities [13,14,26] and some lectins have been shown to elicit antiviral activity by binding
237 with viral glycans of enveloped viruses [15–19] such as HIV and SARS-CoV2. Here, in contrast,
238 we found that the mechanism by which UDA inhibits RABV infection stems primarily from an
239 interaction with the host cells. Previous study shows that N-acetylglucosamine of the host cell
240 is involved in an interaction of RABV with the cells [27]. UDA may thus interact with the cell
241 in a way that prevents RABV entry but not binding.

242 Since RABV typically replicates in muscle tissue upon a bite from a rabid animal and before

243 the virus enters the nervous system, we aimed to develop a physiologically relevant RABV
244 infection model in muscle explants. We isolated intact swine skeletal muscles that were placed
245 under tension in culture medium and that remained for at least 6 days metabolically active.
246 When these muscles strips were infected with RABV, viral antigens were detectable in the tissue
247 and infectious virus particles were released in the culture medium. This demonstrates that
248 RABV infects and productively replicates in swine muscle explants. We then used this
249 physiological relevant model to demonstrate that UDA can completely block RABV infection
250 and subsequent replication in these muscle explants. Thus, the activity of UDA against RABV
251 as observed in BHK cells also translates to muscle tissue demonstrating that this, and possibly,
252 other lectins, may be further studied as alternatives for RIGs. Next, the efficacy of this, or
253 ideally a lectin with more activity against RABV, or a combination of different lections, should
254 be assessed in rodent models of RABV infection.

255 In conclusion, we developed a novel, physiologically relevant RABV infection model by using
256 swine skeletal muscle explants and demonstrate that the plant lectin UDA can prevent RABV
257 infection in this model. UDA and other lectins, may serve as a reference for further studies and
258 may hold promise as an alternative for RIGs in PEP.

Acknowledgements

We are grateful to Tina Van Buyten for excellent technical assistance.

Funding

XW received funding of the China Scholarship Council (CSC) (grant number 201806170087). ACB, GW and ARF were part funded by the UK Department for the Environment, Food and Rural Affairs (Defra) and the devolved Scottish and Welsh governments under grants SE0431.

Author contributions

L. T. and L. T. isolated and dissected the muscle stripes from the freshly euthanized pigs. G. W. provided the rabies virus-mCherry. E. V. D. provided the library of lectins. A. R. F. and A. C. B. advised suggestions for writing. X. W., D. J. and J. N. designed the study and wrote the manuscript.

272 **Table 1. Antiviral activity of lectins against RABV**

Lectin	*Species*	[1]EC_{50} (μg/mL)	CC_{50} (μg/mL)	SI
Gal/GalNAc-specific agglutinins				
PHA-L4	*Phaseolus vulgaris*	47 ± 13	>100	>2.1
RPA	*Robinia pseudoacacia*	5.4 ± 2.5	11 ± 1.4	2.1
RSA	*Rhizoctonia solani*	>100	>100	Na
SJA	*Styphnolobium japonicum*	32 ± 19	>100	>3.2
GalNAc-specific agglutinins				
BPA	*Bauhinia purpurea*	3.2 ± 1.0	9.0 ± 2.1	2.8
CAA	*Caragana arborescens*	95 ± 5	>100	>1.0
DBA	*Dolichos biflorus*	>100	>100	Na
SBA	*Soybean*	>100	>100	Na
WFA	*Wisteria floribunda*	>100	>100	Na
Gal-specific agglutinins				
Jacalin	*Jackfruit*	>100	>100	Na
Morniga G	*Morus nigra*	>100	24 ± 8.6	<0.2
PHA-E	*Phaseolus vulgaris*	47 ± 1.5	86 ± 18	1.8
PNA	*Arachis hypogaea*	>100	>100	Na

GlcNAc-specific agglutinins				
DSL	*Datura stramonium*	57 ± 2.2	69 ± 12.4	1.2
GS II	*Griffonia simplicifolia*	>100	>100	na
Nictaba	*Nicotiana tabacum*	29 ± 3.9	>100	>3.4
UDA	*Urtica dioica*	8.1 ± 1.3	54 ± 6.8	6.7
UEA II	*Ulex europaeus*	>100	>100	na
WGA	*Wheat germ*	21 ± 7.0	17 ± 6.3	0.8
Man/GalNAc-specific agglutinins				
AMA	*Arum maculatum*	7.1 ± 2.9	9.1 ± 2.2	1.3
TLC I	*Tulipa hybrid*	32 ± 5.7	>100	>3.2
Mannose-specific agglutinins				
APA	*Allium porrum L.*	36 ± 11	>100	>2.9
BanLec	*Musa acuminata*	6.2 ± 2.6	40.7 ± 11.5	6.5
Calsepa	*Calystegia sepium*	>100	>100	na
Con A	*Canavalia ensiformis*	13 ± 3.7	22 ± 4	1.7
ConarvA	*Convolvulus arvensis*	91 ± 9.3	>100	>1.1
GNA	*Galanthus nivalis*	>100	>100	na
HHA	*Hippeastrum hybrid*	29 ± 2.3	>100	>3.4

Morniga M	*Morus nigra*	>100	27 ± 14.1	<0.3
NPA	*Narcissus pseudonarcissus*	16 ± 5.4	42 ± 5.8	2.6
PSA	*Pisum sativum*	13 ± 7.5	>100	>7.7
Sialic-acid-specific agglutinin				
ACA	*Amaranthus caudatus*	>100	>100	na
MAA	*Maackia amurensis*	>100	>100	na

Man: mannose, GlcNac: N-acetyl glucosamine, GalNAc: N-acetyl galactosamine, Gal: galactose, Neu5Ac: N-acetylneuraminic acid, SI: selectivity index

[1]EC_{50} and CC_{50} are reported as the average and SD of 3 independent experiments in BHK cells

278



279

280 **Figure 1**. **Anti-RABV activity of UDA, BanLec and PSA in BHK-21J cells.** Serial dilutions
281 of UDA (A), BanLec (B) and PSA (C) were added together with mCherry-RABV (MOI=0.01)
282 to BHK cells. On day 5 p.i. the antiviral activity was determined by quantification of the virus
283 induced mCherry fluorescence. In a parallel experiment the effects of the lectins on cell viability
284 were determined using a viability staining (MTS). Averages and standard deviations of 3
285 independent experiments are presented. Fitting the dose-response curves indicates an EC_{50} of
286 UDA of 4.6 µg/mL and a CC_{50} of 65 µg/mL; an EC_{50} of BanLec of 6 µg/mL and a CC_{50} of 36
287 µg/mL; an EC_{50} of PSA of 18 µg/mL and a CC_{50} of more than 100 µg/mL.

288



289

290 **Figure 2. UDA blocks RABV entry**. Time-of-drug-addition assay. BHK cells were incubated
291 with RABV with or without UDA at 4°C for 1h (-1 – 0 h). After 1h, unattached virus was
292 washed away and UDA was added to the cultures at different time points (0, 0.5, 1, 2, 4 hr p.i.).
293 At 16 h.p.i., intracellular viral RNA was quantified by RT-qPCR. Infected-untreated samples
294 collected at 1 h.p.i. were considered as the virus background. Each condition was tested in 3
295 independent assays and averages and STDEV are indicated. (*P < 0.05; *** P < 0.001, ****P
296 < 0.0001)

297

298

299



300

301

302 **Figure 3**. **UDA inhibits RABV infection by mainly interacting with the cell.** UDA at a final
303 concentration of 25 µg/mL was pre-incubated with RABV or cells at 37°C for 2h. Next, UDA
304 was diluted to a non-inhibitory concentration (1 µg/mL), and cells were further incubated with
305 virus (MOI 0.1) for 3 days at 37°C. Virus infection (%) was determined relative to the untreated
306 condition. Each condition was tested in at least 3 independent experiments and averages and
307 STDEV were calculated. (** $P < 0.01$, ****$P < 0.0001$)

308



309

310 **Figure 4. RABV replicates in swine skeletal muscle explants.** (A) Picture of a swine muscle
311 explant culture. The *biceps femoris* muscle was dissected from freshly euthanized pigs (3
312 months, female) and maintained under tension using pins. (B) Upon infection with RABV
313 (SAD-B19-mCherry), culture supernatant was analyzed each day for levels of vRNA by RT-
314 qPCR. Nine independent cultures were used, median and quartiles are indicated. (C) On day 6
315 p.i. the supernatant of infected (RABV) or non-infected (Mock) muscle cultures was transferred
316 to BHK cells, and after 7 days of incubation, the fluorescence of the cells was visualized by
317 microscopy (the picture is a representative culture of 3 independent experiments). Scale bar:
318 100 µm.

319



Figure 5. UDA inhibits RABV replication in swine skeletal muscle explants. (A) Assessing viability (using resazurin) of muscle explants that had been incubated for 7 days with UDA (25 µg/mL) at 37°C. The resazurin-based viability assay was conducted daily. Blank control: cultures without muscle strips. (B) Muscle explants were infected with RABV in the presence or absence of UDA (25 µg/mL). At 6 d.p.i. the culture supernatant was collected to determine infectious viral titers. (C) On day 6 p.i., muscle strips were fixed and RABV replication was visualized by staining for the viral N-protein (green), cell nuclei were stained with Hoechst (blue). Results of a representative example of 3 independent experiments is shown. Scale bar: 1mm.

References

1. Fooks, A.R.; Cliquet, F.; Finke, S.; Freuling, C.; Hemachudha, T.; Mani, R.S.; Müller, T.; Nadin-Davis, S.; Picard-Meyer, E.; Wilde, H.; et al. Rabies. *Nat. Rev. Dis. Prim.* **2017**, *3*, doi:10.1038/nrdp.2017.91.

2. WHO WHO Guide for Rabies Pre and Post-Exposure Prophylaxis in Humans. *World Heal. Organ.* **2014**, 1–21.

3. Lankester, F.; Hampson, K.; Lembo, T.; Palmer, G.; Taylor, L.; Cleaveland, S. Implementing Pasteur's Vision for Rabies Elimination. *Science (80-.).* **2014**, *345*, 1562 LP – 1564, doi:10.1126/science.1256306.

4. Sreenivasan, N.; Li, A.; Shiferaw, M.; Tran, C.H.; Wallace, R.; Blanton, J.; Knopf, L.; Abela-Ridder, B.; Hyde, T.; Siddiqi, U.R.; et al. Overview of Rabies Post-Exposure Prophylaxis Access, Procurement and Distribution in Selected Countries in Asia and Africa, 2017–2018. *Vaccine* **2019**, *37*, A6–A13, doi:https://doi.org/10.1016/j.vaccine.2019.04.024.

5. zhai, L. li; Wang, H.; Zhao, W.; Zhang, S. feng; Miao, F. ming; Cao, Y.; Chen, C.; Li, Y.F.; Gao, J.; Lv, R. yun; et al. Efficacy of Ormutivimab, a Novel Recombinant Human Anti-Rabies Monoclonal Antibody, in Post-Exposure Prophylaxis Animal Models. *Travel Med. Infect. Dis.* **2022**, *46*, doi:10.1016/j.tmaid.2022.102267.

6. Organization, W.H. Quality Assurance of Pharmaceuticals : A Compendium of Guidelines and Related Materials. Vol. 2, Good Manufacturing Practices and Inspection 2007, Second updated edition 2007.

7. Hemachudha, T.; Ugolini, G.; Wacharapluesadee, S.; Sungkarat, W.; Shuangshoti, S.; Laothamatas, J. Human Rabies: Neuropathogenesis, Diagnosis, and Management. *Lancet Neurol.* **2013**, *12*, 498–513, doi:10.1016/S1474-4422(13)70038-3.

356 8. Hanham, C.A.; Zhao, F.; Tignor, G.H. Evidence from the Anti-Idiotypic Network That
357 the Acetylcholine Receptor Is a Rabies Virus Receptor. *J. Virol.* **1993**, *67*, 530–542,
358 doi:10.1128/JVI.67.1.530-542.1993.

359 9. Lentz, T.L. Rabies Virus Binding to an Acetylcholine Receptor Alpha-Subunit Peptide.
360 *J. Mol. Recognit.* **1990**, *3*, 82–88, doi:10.1002/jmr.300030205.

361 10. Lentz, T.L.; Burrage, T.G.; Smith, A.L.; Crick, J.; Tignor, G.H. Is the Acetylcholine
362 Receptor a Rabies Virus Receptor? *Science (80-.).* **1982**, *215*, 182 LP – 184,
363 doi:10.1126/science.7053569.

364 11. Lentz, T.L.; Burrage, T.G.; Smith, A.L.; Tignor, G.H. The Acetylcholine Receptor as a
365 Cellular Receptor for Rabies Virus. *Yale J. Biol. Med.* **1983**, *56*, 315–322.

366 12. Lafon, M. Rabies Virus Receptors. *J. Neurovirol.* **2005**, *11*, 82–87,
367 doi:10.1080/13550280590900427.

368 13. Sharon, N.; Lis, H. Lectins as Cell Recognition Molecules. *Science* **1989**, *246*, 227–234,
369 doi:10.1126/science.2552581.

370 14. Lis, H.; Sharon, N. Lectins: Carbohydrate-Specific Proteins That Mediate Cellular
371 Recognition. *Chem. Rev.* **1998**, *98*, 637–674, doi:10.1021/cr940413g.

372 15. Balzarini, J. Inhibition of HIV Entry by Carbohydrate-Binding Proteins. *Antiviral Res.*
373 **2006**, *71*, 237–247, doi:https://doi.org/10.1016/j.antiviral.2006.02.004.

374 16. Lam, S.K.; Ng, T.B. Lectins: Production and Practical Applications. *Appl. Microbiol.*
375 *Biotechnol.* **2011**, *89*, 45–55, doi:10.1007/s00253-010-2892-9.

376 17. Hansen, J.E.; Nielsen, C.M.; Nielsen, C.; Heegaard, P.; Mathiesen, L.R.; Nielsen, J.O.
377 Correlation between Carbohydrate Structures on the Envelope Glycoprotein Gp120 of
378 HIV-1 and HIV-2 and Syncytium Inhibition with Lectins. *AIDS* **1989**, *3*, 635–641,
379 doi:10.1097/00002030-198910000-00003.

380 18. Keyaerts, E.; Vijgen, L.; Pannecouque, C.; Van Damme, E.; Peumans, W.; Egberink, H.;
381 Balzarini, J.; Van Ranst, M. Plant Lectins Are Potent Inhibitors of Coronaviruses by
382 Interfering with Two Targets in the Viral Replication Cycle. *Antiviral Res.* **2007**, *75*,
383 179–187, doi:10.1016/j.antiviral.2007.03.003.

384 19. Vanhulle, E.; D'huys, T.; Provinciael, B.; Stroobants, J.; Camps, A.; Noppen, S.; Schols,
385 D.; Van Damme, E.J.M.; Maes, P.; Stevaert, A.; et al. Carbohydrate-Binding Protein
386 from Stinging Nettle as Fusion Inhibitor for SARS-CoV-2 Variants of Concern. *Front.*
387 *Cell. Infect. Microbiol.* **2022**, *12*, 1–18, doi:10.3389/fcimb.2022.989534.

388 20. Marchetti, M.; Mastromarino, P.; Rieti, S.; Seganti, L.; Orsi, N. Inhibition of Herpes
389 Simplex, Rabies and Rubella Viruses by Lectins with Different Specificities. *Res. Virol.*
390 **1995**, *146*, 211–215, doi:10.1016/0923-2516(96)80581-4.

391 21. Conti, C.; Tsiang, H. Effect of Concanavalin A on the Early Events of Rabies Virus
392 Infection of CER Cells. *Intervirology* **1985**, *24*, 166–169, doi:10.1159/000149636.

393 22. Jochmans, D.; Leyssen, P.; Neyts, J. A Novel Method for High-Throughput Screening
394 to Quantify Antiviral Activity against Viruses That Induce Limited CPE. *J. Virol.*
395 *Methods* **2012**, *183*, 176–179, doi:10.1016/j.jviromet.2012.04.011.

396 23. Santé, W.H.O. Rabies Vaccines: WHO Position Paper – April 2018 – Vaccins
397 Antirabiques: Note de Synthèse de l'OMS – Avril 2018. *Wkly. Epidemiol. Rec.* **2018**, *93*,
398 201–219.

399 24. de Melo, G.D.; Hellert, J.; Gupta, R.; Corti, D.; Bourhy, H. Monoclonal Antibodies
400 against Rabies: Current Uses in Prophylaxis and in Therapy. *Curr. Opin. Virol.* **2022**, *53*,
401 1–9, doi:10.1016/j.coviro.2022.101204.

402 25. Peumans, W.J.; Van Damme, E.J. Lectins as Plant Defense Proteins. *Plant Physiol.* **1995**,
403 *109*, 347–352, doi:10.1104/pp.109.2.347.

404 26. Meiers, J.; Siebs, E.; Zahorska, E.; Titz, A. Lectin Antagonists in Infection, Immunity,
405 and Inflammation. *Curr. Opin. Chem. Biol.* **2019**, *53*, 51–67,
406 doi:10.1016/j.cbpa.2019.07.005.

407 27. Conti, C.; Superti, F.; Tsiang, H. Membrane Carbohydrate Requirement for Rabies Virus
408 Binding to Chicken Embryo Related Cells. *Intervirology* **1986**, *26*, 164–168,
409 doi:10.1159/000149696.

410